Trial ID or NCT#

NCT05186818

Status

recruiting iconRECRUITING

Purpose

The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

Official Title

A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Eligibility Criteria

Ages Eligible for Study: 18 Years to 85 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Matthew Wheeler
Matthew Wheeler
Cardiologist, Heart failure cardiologist
Assistant Professor of Medicine (Cardiovascular Medicine)

Contact us to find out if this trial is right for you.

CONTACT

Jennifer Marino
(650) 725-6911